



331 Treble Cove Road
North Billerica, MA 01862

800.362.2668
www.lantheus.com

December 14, 2010

Dear Valued Customer:

Lantheus Medical Imaging, Inc. is pleased to be your supplier of quality products. Together, we have made a significant positive impact in the field of contrast echocardiography. Lantheus is committed to making the investments necessary to facilitate the use and growth of contrast echocardiography. In order to sustain our continued investment in the future while providing you with high quality products and services, Lantheus will be implementing the following price schedule effective January 1, 2011.

DEFINITY® Vial for (Perflutren Lipid Microspheres) Injectable Suspension

Price per Vial	Price Per Box
\$136.00	\$544.00

Pricing above is quoted F.O.B destination for standard 2-3 day delivery. Expedited orders will incur a shipping fee of \$27.50. This price change will not apply to established GPO price schedules or any existing contractual agreements.

If you have any questions, please contact your Sales Representative or the Lantheus Customer Service Department at 1-800-299-3431.

Thank you for your continued support of DEFINITY® and Lantheus Medical Imaging. We look forward to serving you as we continue to work together to advance the field of echocardiography and support the patients you serve.

Sincerely,

A handwritten signature in black ink that reads "Karen R. Stewich".

Karen Stewich
Director Sales Administration
Lantheus Medical Imaging, Inc.

Please see attached Indications, Contraindications, and Important Safety Information and full Prescribing Information, including boxed **WARNING** regarding serious cardiopulmonary reactions.

INDICATIONS

Activated DEFINITY[®] (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The safety and efficacy of DEFINITY[®] with exercise stress or pharmacologic stress testing have not been established.

CONTRAINDICATIONS

Do not administer DEFINITY[®] to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.

IMPORTANT SAFETY INFORMATION

WARNING: Serious Cardiopulmonary Reactions

Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration.

- Assess all patients for the presence of any condition that precludes DEFINITY[®] administration (see CONTRAINDICATIONS).
- In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor vital sign measurements, electrocardiography and cutaneous oxygen saturation during and for at least 30 minutes after DEFINITY[®] administration (see WARNINGS).
- Always have resuscitation equipment and trained personnel readily available.

In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration (see ADVERSE REACTIONS). The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.

Please see full Prescribing Information, including boxed **WARNING** regarding serious cardiopulmonary reactions below.